Harvard Apparatus Regenerative Technology, Inc.
HRGNOTCHealthcare · Surgical & Medical Instruments & Apparatus · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $704,000 | $430,000 | $103,000 | — | $0 | $0 |
| Operating income | −$6.9M | −$7.7M | −$9.0M | −$6.2M | −$8.6M | −$5.3M |
| Net income | −$6.9M | −$7.7M | −$8.9M | −$6.1M | −$8.0M | −$4.9M |
| Total assets | $2.7M | $4.4M | $2.6M | $2.4M | $1.9M | $2.1M |
| Total liabilities | $1.6M | $1.2M | $968,000 | $1.4M | $4.9M | $951,000 |
| Equity | $1.1M | $3.2M | $1.6M | −$3.2M | −$3.0M | $1.1M |
| EPS (diluted) | $-0.42 | $-0.52 | $-0.67 | $-0.55 | $-0.79 | $-0.55 |
| Shares out. | 15.9M | 13.9M | 12.2M | 10.8M | 9.4M | 8.3M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −982.2%
- Net margin
- −975.7%
- Return on equity
- −649.9%
- Return on assets
- −256.6%
- Return on capital (ROCE)
- −605.0%
- Liabilities / assets
- 60.5%
- Debt / equity
- 1.53×
- Book value / share
- $0.07
- Revenue growth (YoY)
- 63.7%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -145.71distress
- Accruals / assets
- −113.6%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 severe● 3 warning● 2 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 17, 2021
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2021
- NT 10-Qmissed a reporting deadline ↗Nov 14, 2017
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| He JunliOfficer — CEO | Nov 25, 2025 | Buy | 3,000 | $1.70 |
| He JunliOfficer — CEO | Sep 30, 2025 | Buy | 300 | $1.98 |
| He JunliOfficer — CEO | Sep 2, 2025 | Buy | 11,225 | $1.85 |
| He JunliOfficer — CEO | Aug 21, 2025 | Buy | 4,050 | $1.72 |
| He JunliOfficer — CEO | Dec 24, 2024 | Buy | 2,299 | $2.87 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 60 | 1.0 | -62.7% |
| Apr 30, 2026 | 161 | 1.0 | +847.1% |
| Apr 15, 2026 | 17 | 1.0 | 0.0% |
| Mar 31, 2026 | 17 | 1.0 | -5.6% |
| Mar 13, 2026 | 18 | 1.0 | 0.0% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureApr 28, 2026
- Terminated a material agreementApr 15, 2026
- Entered a material agreement · Unregistered equity saleJan 6, 2026
- Entered a material agreement · Unregistered equity saleJul 14, 2025
- Shareholder voteJun 24, 2025
- Changed auditorApr 14, 2025
- Entered a material agreementNov 6, 2024
- Director / officer changeAug 27, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-QMay 13, 2026
- 8-KFORM 8-KApr 28, 2026
- DEF 14AFORM DEF 14AApr 23, 2026
- 8-KFORM 8-KApr 15, 2026
- 10-KFORM 10-KMar 19, 2026
- DJan 6, 2026
- 8-KFORM 8-KJan 6, 2026
- 4FORM 4Dec 1, 2025
- 10-QFORM 10-QNov 7, 2025
- 4FORM 4Oct 1, 2025
- 4FORM 4Sep 24, 2025
- 4FORM 4Sep 2, 2025
- 10-QFORM 10-QAug 11, 2025
- DJul 14, 2025
- 8-KFORM 8-KJul 14, 2025
Corporate family
Spun off from Harvard BioscienceHBIO · Nov 1, 2013
From the spin-off filings we track. Follow a company to walk its own history.
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.